Sun Pharmaceutical Industries Ltd Declines 1.85% Despite 52-Week Highs and Elevated Derivatives Activity

18 May: New 52-Week High and Surge in Call Option Activity

Sun Pharmaceutical Industries Ltd began the week on a strong note, hitting a new 52-week high of Rs.1,891.15 on 18 May 2026, closing at Rs.1,905.20 with a 1.34% gain. This milestone reflected sustained momentum supported by robust fundamentals including net-debt-free status, strong sales growth at an annualised 11.37%, and operating profit growth of 20.79%. The stock outperformed the Sensex, which declined 0.35% that day, highlighting relative strength.

Simultaneously, the derivatives market saw a surge in call option activity, particularly at the Rs.1,900 strike price, with 18,274 contracts traded and open interest at 12,271 contracts. This bullish positioning suggested investor confidence in further upside potential ahead of the 26 May expiry. The stock’s technical indicators were predominantly positive, trading above all major moving averages and supported by bullish MACD and Bollinger Bands signals.

19 May: All-Time High and Rating Downgrade Amid Valuation Concerns

The stock continued its upward trajectory on 19 May, reaching an all-time high of Rs.1,917.15, despite a slight intraday decline of 1.21% to close at Rs.1,882.15. This marked a 4.8% gain over four consecutive trading days. Sun Pharma’s market capitalisation rose to Rs.4,57,121 crores, maintaining its position as the largest entity in the Pharmaceuticals & Biotechnology sector.

However, MarketsMOJO downgraded the stock’s rating from 'Strong Buy' to 'Buy' on 18 May, citing stretched valuation metrics. The price-to-earnings ratio stood at 37.65, with a price-to-book value of 5.87 and a PEG ratio of 12.78, indicating that the stock’s price appreciation had outpaced earnings growth, which was modest at 3% over the past year. Despite strong operational metrics such as a 25.07% ROCE and 14.84% ROE, the valuation shift signalled caution.

Technical indicators remained mixed but generally positive, with bullish weekly MACD and Bollinger Bands offset by mild monthly bearishness in some oscillators. Institutional ownership remained robust at 37.04%, supporting market stability.

20-21 May: Consolidation and Mixed Price Movements

On 20 May, the stock price marginally declined by 0.09% to Rs.1,880.50, while the Sensex gained 0.28%. The following day, 21 May, saw a modest recovery with a 0.57% increase to Rs.1,891.15, outperforming the Sensex’s 0.12% gain. Trading volumes remained healthy, reflecting ongoing investor interest amid a consolidating price range.

These days were characterised by the stock maintaining its position above key moving averages, signalling sustained medium- to long-term strength despite short-term fluctuations. Delivery volumes showed some volatility, with a notable drop on 21 May, suggesting cautious accumulation or profit booking by market participants.

22 May: Open Interest Surge Amid Price Decline and Mixed Signals

The week closed on a cautious note as Sun Pharma’s share price fell 2.43% to Rs.1,845.20, underperforming the Sensex which rose 0.21%. Despite the price decline, the derivatives market saw a significant 12.3% surge in open interest to 1,83,379 contracts, accompanied by robust futures and options volumes. This divergence indicated increased speculative positioning and hedging activity rather than outright buying in the cash market.

Price action showed the stock trading below its 5-day moving average but above longer-term averages, suggesting short-term weakness amid a sustained uptrend. Delivery volumes dropped sharply by 45.13% compared to the five-day average, reinforcing the notion of subdued cash market participation. The large notional value in options and futures pointed to complex strategies by traders balancing optimism with risk management ahead of expiry.

Weekly Price Performance: Sun Pharma vs Sensex

Key Takeaways

Positive Signals: Sun Pharma demonstrated strong fundamental health with net-debt-free status, consistent sales and profit growth, and robust liquidity. The stock’s ability to hit new 52-week highs early in the week and sustained institutional ownership of 37.04% underscore its market leadership and investor confidence. Technical indicators largely supported an uptrend, with the stock trading above key moving averages and showing bullish momentum in several oscillators.

Cautionary Signals: The downgrade from 'Strong Buy' to 'Buy' and the shift to a very expensive valuation grade highlight concerns about stretched price multiples relative to earnings growth. The PEG ratio of 12.78 and high P/E of 37.65 suggest elevated expectations that may limit near-term upside. The sharp decline in delivery volumes and the price drop on 22 May amid a surge in derivatives open interest point to increased speculative positioning and potential short-term volatility.

Conclusion

Sun Pharmaceutical Industries Ltd’s week was marked by a strong start with new highs and bullish derivatives activity, followed by a more cautious close reflecting valuation pressures and mixed market signals. While the company’s fundamentals remain solid and its sector dominance intact, the premium valuation and recent price weakness suggest investors should monitor earnings delivery and market developments closely. The surge in open interest and active options trading indicate that market participants are positioning for potential volatility ahead, balancing optimism with risk management. Overall, the stock’s performance this week underscores the complex dynamics at play in large-cap pharmaceutical equities amid evolving market conditions.

Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →